Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.91
-0.15 (-1.49%)
At close: Aug 14, 2025, 4:00 PM
9.91
0.00 (0.00%)
After-hours: Aug 14, 2025, 4:10 PM EDT

Arcus Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Net Income
-298-283-307-26753-123
Upgrade
Depreciation & Amortization
10108643
Upgrade
Asset Writedown & Restructuring Costs
-20----
Upgrade
Loss (Gain) From Sale of Investments
-19-25-19-5-
Upgrade
Stock-Based Compensation
677673655522
Upgrade
Other Operating Activities
810101131
Upgrade
Change in Accounts Receivable
132815704-17-1
Upgrade
Change in Accounts Payable
153-18-59
Upgrade
Change in Unearned Revenue
-163-56-68-112-368188
Upgrade
Change in Other Net Operating Assets
2847-17231412
Upgrade
Operating Cash Flow
-339-170-306438-256111
Upgrade
Capital Expenditures
-3-6-24-6-26-3
Upgrade
Investment in Securities
194-78218-40422-431
Upgrade
Other Investing Activities
----3--
Upgrade
Investing Cash Flow
191-84194-413-4-434
Upgrade
Long-Term Debt Issued
-47----
Upgrade
Net Debt Issued (Repaid)
9647----
Upgrade
Issuance of Common Stock
1502373323232439
Upgrade
Repurchase of Common Stock
-6-7----
Upgrade
Other Financing Activities
---105-
Upgrade
Financing Cash Flow
2402773333237439
Upgrade
Net Cash Flow
9223-7958-23116
Upgrade
Free Cash Flow
-342-176-330432-282108
Upgrade
Free Cash Flow Margin
-130.53%-68.22%-282.05%385.71%-73.63%138.46%
Upgrade
Free Cash Flow Per Share
-3.53-1.95-4.466.00-3.811.97
Upgrade
Cash Interest Paid
11----
Upgrade
Cash Income Tax Paid
--53--
Upgrade
Levered Free Cash Flow
-113-41.25-187.75617.75-644.7540.73
Upgrade
Unlevered Free Cash Flow
-109.25-38.75-186.5619-644.7540.73
Upgrade
Change in Working Capital
-10722-71623-376208
Upgrade
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q